There is little rationale for direct-to-consumer advertising of prescription drugs. Most new drugs offer little if any therapeutic advantage over existing products. Direct-to-consumer advertisements frequently downplay safety information. Physicians are highly ambivalent about prescribing advertised drugs requested by patients. There is no evidence that direct-to-consumer advertising results in any improvement in health outcomes.
Get full access to this article
View all access options for this article.
References
1.
AdamsC. (2001), “FDA Scrambles to Police Truthfulness of Ads,”The Wall Street Journal, (January 2), A24.
2.
AvornJ., ChenM., and HartleyR. (1982), “Scientific Versus Commercial Sources of Influence on the Prescribing Behavior of Physicians,”American Journal of Medicine, 73(1), 4–8.
3.
BeckerM.H., StolleyP.D., LasagnaL., McEvillaJ.D., and SloaneL.M. (1972), “Differential Education Concerning Therapeutics and Resultant Physician Prescribing Patterns,”Journal of Medical Education, 47(2), 118–27.
4.
BellRobert A., KravitzRichard L., and WilkesMichael S. (1999), “Direct-to-Consumer Prescription Drug Advertising and the Public,”Journal of General Internal Medicine, 14(11), 651–57.
5.
BellRobert A., WilkesMichael S., and KravitzRichard L. (2000a), “The Educational Value of Consumer-Targeted Prescription Drug Print Advertising,”Journal of Family Practice, 49(12), 1092–98.
6.
BellRobert A., WilkesMichael S., and KravitzRichard L. (2000b), “Direct-to-Consumer Prescription Drug Advertising, 1989–1998: A Content Analysis of Conditions, Targets, Inducements, and Appeals,”Journal of Family Practice, 49(4), 329–35.
7.
BeringsD., BlondeelL., and HabrakenH. (1994), “The Effect of Industry-Independent Drug Information on the Prescribing of Benzodiazepines in General Practice,”European Journal of Clinical Pharmacology, 46(6), 501–505.
8.
BlondeelL., CannoodtL., DeMeyeereM., and ProesmansH. (1987), “Prescription Behaviour of 358 Flemish General Practitioners,” paper presented at International Society of General Medicine, Prague (Spring).
9.
BonaccorsoS.N., and SturchioJ.L. (2002), “Direct to Consumer Advertising Is Medicalising Normal Human Experience: Against,”British Medical Journal, 324(7342), 910–11.
10.
BowerA.D., and BurkettG.L. (1987), “Family Physicians and Generic Drugs: A Study of Recognition, Information Sources, Prescribing Attitudes, and Practices,”Journal of Family Practice, 24(6), 612–16.
11.
CalfeeJohn E. (2002), “Public Policy Issues in Direct-to-Consumer Advertising of Prescription Drugs,”Journal of Public Policy & Marketing, 21(Fall), 174–93.
12.
CaudillT.S., JohnsonM.S., RichE.C., and McKinneyW.P. (1996), “Physicians, Pharmaceutical Sales Representatives, and the Cost of Prescribing,”Archives of Family Medicine, 5(4), 201–206.
13.
Consumer Reports (1996), “Drug Advertising: Is This Good Medicine?” (June), 62–63.
14.
CormackM.A., and HowellsE. (1992), “Factors Linked to the Prescribing of Benzodiazepines by General Practice Principals and Trainees,”Family Practice, 9(4), 466–71.
15.
DrakeDonald, and UhlmanMarian (1993), Making Medicine, Making Money.Kansas City, MO: Andrews and McMeel.
16.
FerryM.E., LamyP.P., and BeckerL.A. (1985), “Physicians’ Knowledge of Prescribing for the Elderly: A Study of Primary Care Physicians in Pennsylvania,”Journal of the American Geriatric Society, 33(9), 616–21.
17.
FindlaySteven (2001), Prescription Drugs and Mass Media Advertising, 2000.Washington DC: National Institute of Health Care Management, (accessed June 15), [available at www.nihcm.org].
18.
HaayerFlora (1982), “Rational Prescribing and Sources of Information,”Social Science & Medicine, 16(23), 2017–23.
19.
HardonAnita, and HayesElizabeth, eds. (1997), Reproductive Rights in Practice: A Feminist Report on Quality of Care.London: Zed Books.
20.
HerxheimerAndrew (1998), “Many NSAID Users Who Bleed Don't Know When to Stop,”British Medical Journal, 316(7130), 492.
21.
JuniP., RutjesA., and DieppeP.A. (2002), “Are Selective COX 2 Inhibitors Superior to Traditional Non Steroidal Anti-inflammatory Drugs?”British Medical Journal, 324(7349), 1287–88.
22.
KaitinK.I., PhelanN.R., RaifordD., and MorrisB. (1991), “Therapeutic Ratings and End-of-Phase II Conferences: Initiatives to Accelerate the Availability of Important New Drugs,”Journal of Clinical Pharmacology, 31(1), 17–24.
23.
KoernerC. (1999), “The Regulation of Direct-to-Consumer Promotion of Prescription Drugs,” paper presented at Health Canada Multi-stakeholders’ Consultation on Direct-to-Consumer Advertising, Aylmer, Québec (April 14).
24.
LasserK.E., AllenP.D., WoolhandlerS.J., HimmelsteinD.U., WolfeS.M., and BorD.H. (2002), “Timing of New Black Box Warnings and Withdrawals for Prescription Medications,”Journal of the American Medical Association, 287(17), 2215–20.
25.
LillD.J., and PetersonR.T. (2001), “Older Adult Portrayal in Television Commercials by Pharmaceutical Manufacturers: An Analysis,”Journal of Pharmaceutical Marketing & Management, 14(1), 1–96.
26.
LinnL.S., and DavisM.S. (1972), “Physicians’ Orientation Toward the Legitimacy of Drug Use and their Preferred Source of New Drug Information,”Social Science & Medicine, 6(2), 199–203.
27.
LylesA. (2002), “Direct Marketing of Pharmaceuticals to Consumers,”Annual Review of Public Health, 23(1), 73–91.
28.
MapesP. (1977), “Aspects of British General Practitioners’ Prescribing,”Medical Care, 15(5), 371–81.
29.
MelilloW. (1999), “FDA Cites Most DTC Drug Spots,”Adweek, 40(7), 4.
30.
MertensG. (1998), “Direct to Consumer Advertising: Global Drug Promotion,” in Healthcare.London: Financial Times, 16.
31.
MintzesBarbara, BarerMorris L., KravitzRichard L., KazanjianArminée, BassettKen, LexchinJoel (2002), “Influence of Direct to Consumer Pharmaceutical Advertising and Patients’ Requests on Prescribing Decisions: Two Site Cross Sectional Survey,”British Medical Journal, 324(7332), 278–79.
32.
OstroveN. (2000), “What's New in the Regulation of DTC Promotion?” (posted June 14), (accessed May 17, 2002), [available at www.fda.gov/cder/ddmac/nodia260/index.htm].
33.
Patented Medicine Prices Review Board (2000), Annual Report 2000.Ottawa, Canada: Supply and Services Canada.
34.
PowersR.L., HalbritterK.A., ArbogastJ.G., NeelyJ.L., and WilliamsA.J. (1998), “Do Interactions with Pharmaceutical Representatives Influence Antihypertensive Medication Prescribing Practices of Family Medicine and General Internal Medicine Physicians?”Journal of General Internal Medicine, 13(supplement), 13.
35.
Prescrire International (2001), “A Look Back at 2000: Overabundance and Deregulation,”10 (February), 52–54.
RothMartin S. (1996), “Patterns in Direct-to-Consumer Prescription Drug Print Advertising and Their Public Policy Implications,”Journal of Public Policy & Marketing, 15(1), 63–75.
38.
SilversidesAnn (2001), “Looser Ad Rules a Headache for Drug Plans. Direct-to-Consumer Advertising Will Send Costs Soaring, Employers Warn,”Globe and Mail, (September 18), H1.
39.
SmithD. (1998), “DTC: One Year Later,”Pharmaceutical Executive, 18(11), DTC18, DTC20.
40.
SpingarnR.W., BerlinJ.A., and StromB.L. (1996), “When Pharmaceutical Manufacturers’ Employees Present Grand Rounds, What Do Residents Remember?”Academic Medicine, 71(1), 86–88.
41.
Therapeutics Initiative (2001/2002), “Cox-2 Inhibitors Update: Do Journal Articles Tell the Full Story?”Therapeutics Letter, 43, (accessed June 15, 2002), [available at www.ti.ubc.ca/PDF/43pdf].
42.
VallisM. (2002), “Antidepressant Puts Newborns at Risk, Study Says,”National Post, (May 7), A2.
43.
WazanaA. (2000), “Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?”Journal of the American Medical Association, 283(3), 373–80.
44.
WilkesMichael S., BellRobert A., and KravitzRichard L. (2000), “Direct-to-Consumer Prescription Drug Advertising: Trends, Impact, and Implications,”Health Affairs, 19(2), 110–28.
45.
WolfeSidney (2001), “Testimony Before the Subcommittee on Consumer Affairs Hearing, Senate Commerce Committee Hearing on Direct-to-Consumer (DTC) Advertising,” Washington, DC, (posted July 24), (accessed June 10, 2002), [available at [http://www.citizen.org/publications/release.cfm?ID=6785].
46.
WoloshinSteven, SchwartzLisa M., TremmelJennifer, and Gilbert WelchH. (2001), “Direct-to-Consumer Advertisements for Prescription Drugs: What Are Americans Being Sold?”Lancet, 358(9288), 1141–46.
47.
WoodA. (1999), “The Safety of New Medicines: The Importance of Asking the Right Questions,”Journal of the American Medical Association, 281(18), 1753–54.
48.
World Health Organization (1988), Ethical Criteria for Medicinal Drug Promotion.Geneva, Switzerland: World Health Organization.
